People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology, Other, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Asklepios BioPharmaceutical, Inc. | — | Biotechnology | Series D+ | $199.7M | $8.2B | 2019 |
| Kyverna Therapeutics, Inc. | — | Biotechnology | Series D+ | $152.0M | $4.0B | 2021 |
| Roka BioScience, Inc. | — | Biotechnology | Series B | $141.4M | $893.0M | 2013 |
| Ascend Advanced Therapies Group, Inc. | — | Other | Series D+ | $130.6M | $1.2B | 2024 |
| Auxogyn Inc | — | Other Health Care | Series B | $73.1M | $327.3M | 2015 |
| Ascend Gene & Cell Therapies Ltd. | — | Other | Series C | $66.6M | $680.5M | 2023 |
| XDx, Inc. | — | Biotechnology | Series B | $44.5M | $879.9M | 2010 |
| Cell Design Labs, Inc. | — | Biotechnology | Series B | $26.9M | $158.8M | 2016 |
| Veracyte, Inc. | — | Other Health Care | Series A | $22.1M | $258.2M | 2010 |
| Proteogenix Inc | — | Biotechnology | Series A | $8.0M | $144.6M | 2009 |
| Firefly Neuroscience, Inc. | — | Other Health Care | Seed | $2.8M | $4.8M | 2023 |
| BNA Chicago LLC | — | Other | Seed | $1.9M | $35.3M | 2011 |
Fred Cohen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Fred Cohen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Brook Byers | 3 | 13 |
| Beth Seidenberg | 2 | 15 |
| Vijay Lathi | 2 | 8 |
| G. Steven Burrill | 2 | 7 |
| Brian Atwood | 2 | 6 |
| Andrew Sinclair | 2 | 5 |
| David Levison | 2 | 3 |
| Balaji Muralidhar | 2 | 3 |
| Fred G. Cohen | 2 | 3 |
| William Hawkins | 2 | 2 |
| Peter Maag | 2 | 2 |
| Timothy Funnell | 2 | 2 |
| Michael Beecham | 2 | 2 |
| Michael Goldberg | 1 | 11 |
| Jonathan Silverstein | 1 | 10 |
| Brian G. Atwood | 1 | 8 |
| Simeon George | 1 | 8 |
| Greg Garfield | 1 | 8 |
| John Schilling | 1 | 6 |
| Ryan Jones | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.